Accession Number : AD1013500

Title :   A New Paradigm for the Treatment of Ovarian Cancer: The Use of Epigenetic Therapy to Sensitize Patients to Immunotherapy and Chemotherapy

Descriptive Note : Technical Report,30 Sep 2014,29 Sep 2015

Corporate Author : The Johns Hopkins University Baltimore United States

Personal Author(s) : Baylin,Stephen B

Full Text :

Report Date : 01 Oct 2015

Pagination or Media Count : 67

Abstract : The overall goal of this project remains to bring epigenetic therapy strategies to have major impact forthe management of advanced ovarian cancer (OC). In the first year, we have made exciting advances for this purpose and especially for the concept of utilizing low dose epigenetic therapy to target DNA demethylation and histone deacetylase inhibition (HDACi) to maximize responses to immune checkpoint therapy. We identified, from studies of multiple OC cell lines how low doses of the DNA demethylation agents, azacytidine (AZA) and deoxy-azacytidine (DAC) induce a deep immune attraction signature.

Descriptors :   Ovarian cancer , therapeutics

Distribution Statement : APPROVED FOR PUBLIC RELEASE